CN113558146A - Feed buffering agent, preparation method and application thereof, and feed using feed buffering agent - Google Patents
Feed buffering agent, preparation method and application thereof, and feed using feed buffering agent Download PDFInfo
- Publication number
- CN113558146A CN113558146A CN202010359860.XA CN202010359860A CN113558146A CN 113558146 A CN113558146 A CN 113558146A CN 202010359860 A CN202010359860 A CN 202010359860A CN 113558146 A CN113558146 A CN 113558146A
- Authority
- CN
- China
- Prior art keywords
- feed
- parts
- rumen
- buffer
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000006172 buffering agent Substances 0.000 title abstract description 26
- 239000000872 buffer Substances 0.000 claims abstract description 123
- 241000282849 Ruminantia Species 0.000 claims abstract description 37
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims abstract description 35
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 33
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 33
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 33
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000001632 sodium acetate Substances 0.000 claims abstract description 33
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 33
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 27
- 208000010444 Acidosis Diseases 0.000 claims abstract description 25
- 230000007950 acidosis Effects 0.000 claims abstract description 25
- 208000026545 acidosis disease Diseases 0.000 claims abstract description 25
- 235000012245 magnesium oxide Nutrition 0.000 claims abstract description 7
- 239000012141 concentrate Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 5
- 235000013325 dietary fiber Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 210000004767 rumen Anatomy 0.000 abstract description 77
- 230000000694 effects Effects 0.000 abstract description 43
- 235000013336 milk Nutrition 0.000 abstract description 32
- 239000008267 milk Substances 0.000 abstract description 32
- 210000004080 milk Anatomy 0.000 abstract description 32
- 230000006651 lactation Effects 0.000 abstract description 20
- 235000021243 milk fat Nutrition 0.000 abstract description 18
- 241001465754 Metazoa Species 0.000 abstract description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 14
- 210000005075 mammary gland Anatomy 0.000 abstract description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract description 12
- 230000009286 beneficial effect Effects 0.000 abstract description 11
- 230000001965 increasing effect Effects 0.000 abstract description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 8
- 230000003139 buffering effect Effects 0.000 abstract description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 238000000855 fermentation Methods 0.000 abstract description 4
- 230000004151 fermentation Effects 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 230000036528 appetite Effects 0.000 abstract description 3
- 235000019789 appetite Nutrition 0.000 abstract description 3
- 239000003674 animal food additive Substances 0.000 abstract description 2
- 241000283707 Capra Species 0.000 description 44
- 239000008280 blood Substances 0.000 description 43
- 210000004369 blood Anatomy 0.000 description 43
- 239000002158 endotoxin Substances 0.000 description 18
- 229920006008 lipopolysaccharide Polymers 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 239000012530 fluid Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 235000013365 dairy product Nutrition 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 206010016717 Fistula Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003890 fistula Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 210000004731 jugular vein Anatomy 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- 102100029855 Caspase-3 Human genes 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 238000013494 PH determination Methods 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 101710170789 Protein bax Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000004002 Vascular Fistula Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000021408 high quality diet Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- -1 hydrogen ions Chemical class 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- JBYXPOFIGCOSSB-UQGDGPGGSA-N rumenic acid Chemical compound CCCCCC\C=C/C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-UQGDGPGGSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000010023 transfer printing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/22—Compounds of alkali metals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Fodder In General (AREA)
Abstract
The invention provides a feed buffering agent, a preparation method and application thereof as well as a feed using the same, and relates to the technical field of feed additives, the feed buffering agent provided by the invention mainly comprises sodium bicarbonate, magnesium oxide, sodium acetate and sodium butyrate, and the sodium bicarbonate can play an acid-base buffering effect on rumen and maintain an ideal rumen fermentation environment; the magnesium oxide can maintain beneficial biological flora in the gastrointestinal tract and increase the number of beneficial bacteria in the intestinal tract; sodium acetate can increase acetic acid concentration in rumen, and improve milk fat rate; sodium butyrate can increase ruminant appetite. The feed buffer provided by the invention has certain effects of preventing and relieving rumenic acidosis of the ruminant, maintaining the number of beneficial flora in the intestinal tract of the ruminant, improving the health state of an organism, improving the lactation performance of the lactating animal, improving the milk quality, increasing the milk fat, the milk sugar and the milk yield content, and enhancing the protection effect on mammary gland by matching the specific components.
Description
Technical Field
The invention relates to the technical field of feed additives, in particular to a feed buffering agent, a preparation method and application thereof, and a feed using the same.
Background
Lactation is a complex process, and the main metabolic feature of lactating animals in the process of producing milk is high energy demand. At present, due to the shortage of cultivated land and grassland, the coarse material is deficient or the quality is not good in China. Therefore, the high concentrate feed is usually added in production to meet the requirement of high energy of the lactating cows or dairy goats, but studies have proved that when the lactating cows or dairy goats are fed with the high concentrate feed for a long time, rumen pH is reduced, which in turn causes the excessive release of Subacute rumen acidosis (SARA) and abnormal products such as Lipopolysaccharides (LPS), which exceed the intestinal detoxification capability and are shifted to blood, thus causing inflammatory reaction of the organism and metabolic disturbance of the liver, affecting the synthesis and content of milk components in the mammary gland, and finally causing the reduction of milk quality. That is to say, when SARA is adopted, the reduction of the pH value of rumen and the excessive release of abnormal products LPS and the like are key links which cause the reduction of milk quality caused by the long-term feeding of high concentrate. Therefore, controlling the SARA of ruminants and improving the pH value of rumen can be one way to relieve the milk quality reduction caused by long-term feeding of high concentrate. SARA is currently a problem of great concern to dairy farmers because it is associated with the development of various diseases such as mastitis, milk fat suppression, laminitis, liver abscesses and even death. The harm brought by high-precision materials seriously influences the healthy development of the milk industry, and how to regulate the negative effect is very important.
Buffering agents are commonly used to prevent ruminal acidosis in ruminants. The buffering agent can not only improve the reduction of the milk fat rate caused by the feeding of high-concentrate daily ration by the ruminant, but also improve the production performance of the ruminant. Therefore, the addition of buffers to the ration has become an important measure to improve animal performance in recent years. At present, buffering agents commonly used for ruminants at home and abroad include sodium bicarbonate, sodium acetate, sodium butyrate, magnesium oxide, calcium carbonate and the like. A single buffer is researched more, and the research on the comprehensive regulation and control of ruminants by two or more than two composite buffers is not reported much.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
It is a first object of the present invention to provide a feed buffer to alleviate at least one of the technical problems of the prior art.
The second purpose of the invention is to provide the preparation method of the feed buffer, the method has simple process and convenient operation, can save a large amount of manpower and material resources and reduce the cost, and the prepared feed buffer has good effect of improving the rumen acidosis of ruminants.
The third purpose of the invention is to provide the application of the feed buffering agent in the preparation of products for preventing and/or treating rumen acidosis of ruminants.
A fourth object of the present invention is to provide a feed which is effective in improving the lactation performance of lactating animals while preventing and/or treating ruminal acidosis in ruminants.
The invention provides a feed buffering agent, which mainly comprises the following components:
sodium bicarbonate, magnesium oxide, sodium acetate, and sodium butyrate.
Further, the feed buffer mainly comprises the following components in parts by weight:
1-10 parts of sodium bicarbonate, 1-10 parts of magnesium oxide, 5-15 parts of sodium acetate and 5-15 parts of sodium butyrate.
Further, the feed buffer mainly comprises the following components in parts by weight:
2-8 parts of sodium bicarbonate, 2-8 parts of magnesium oxide, 8-12 parts of sodium acetate and 8-12 parts of sodium butyrate.
Further, the feed buffer mainly comprises the following components in parts by weight:
6 parts of sodium bicarbonate, 6 parts of magnesium oxide, 10 parts of sodium acetate and 10 parts of sodium butyrate.
The invention also provides a preparation method of the feed buffer, which is characterized in that sodium bicarbonate, magnesium oxide, sodium acetate and sodium butyrate in parts by weight of the formula are uniformly mixed to obtain the feed buffer.
The invention also provides the application of the feed buffer or the feed buffer prepared by the preparation method in preparing a product for preventing and/or treating ruminant rumen acidosis.
Further, the product is a feed.
In addition, the invention also provides a feed which comprises a basal feed and the feed buffering agent or the feed buffering agent prepared by the preparation method.
Further, the basal feed comprises roughage and/or concentrate;
preferably, the basal feed comprises a concentrate.
Further, the mass ratio of the basal feed to the feed buffer is 25-35: 1, preferably 31: 1.
The feed buffering agent provided by the invention mainly comprises sodium bicarbonate, magnesium oxide, sodium acetate and sodium butyrate, wherein the sodium bicarbonate can play an acid-base buffering effect on rumen and maintain an ideal rumen fermentation environment; the magnesium oxide can maintain beneficial biological flora in the gastrointestinal tract and increase the number of beneficial bacteria in the intestinal tract; sodium acetate can increase acetic acid concentration in rumen, and improve milk fat rate; sodium butyrate can increase ruminant appetite. The feed buffer provided by the invention has certain effects of preventing and relieving rumenic acidosis of the ruminant, maintaining the number of beneficial flora in the intestinal tract of the ruminant, improving the health state of an organism, improving the lactation performance of the lactating animal, improving the milk quality, increasing the milk fat, the milk sugar and the milk yield content, and enhancing the protection effect on mammary gland by matching the specific components.
The preparation method of the feed buffering agent provided by the invention is characterized in that the components of the formula are uniformly mixed, the method is simple in process and convenient to operate, a large amount of manpower and material resources can be saved, the cost is reduced, and the prepared feed buffering agent has good effects of improving ruminant rumen acidosis and improving lactation performance.
The feed provided by the invention comprises a basic feed and the feed buffering agent provided by the invention, and the feed can effectively improve the lactation performance of lactating animals on the basis of ensuring the nutrition supply, and simultaneously prevent and/or treat ruminal acidosis of the ruminants. The feed is supplemented with a proper amount of feed buffer, which is a beneficial feeding mode.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 is a graph showing the effect of feed buffer on the milk production of lactating goats according to the experimental examples of the present invention;
FIG. 2 is a graph showing the results of the effect of feed buffer on the milk fat content of lactating goats, as provided in the experimental examples of the present invention;
FIG. 3 is a graph showing the results of the effect of feed buffer on the lactose content of lactating goats, as provided by the experimental examples of the present invention;
FIG. 4 is a graph showing the results of the effect of feed buffer on the rumen pH of lactating goats, as provided by the experimental examples of the present invention;
FIG. 5A is a graph showing the effect of feed buffer on the content of LPS in the rumen of a lactating goat in accordance with an exemplary embodiment of the present invention;
FIG. 5B is a graph showing the results of the effect of feed buffer on LPS content in lactating goat blood provided by the experimental example of the present invention;
FIG. 6A is a graph showing the effect of a feed buffer on Caspase-3 in lactating goats in accordance with an illustrative embodiment of the present invention;
FIG. 6B is a graph showing the effect of a feed buffer on Caspase-9 in lactating goats in accordance with an illustrative embodiment of the present invention;
FIG. 6C is a graph showing the effect of feed buffer on apoptosis protein Bax of lactating goats in accordance with the experimental examples of the present invention;
FIG. 6D is a graph showing the effect of the feed buffer on apoptosis protein Bcl-2 of lactating goats in accordance with the experimental examples of the present invention;
FIG. 7A is a graph showing the results of the detection of the blood lactic acid content of lactating goats by the feed buffer according to the experimental examples of the present invention;
FIG. 7B is a graph showing the results of the measurement of histamine content in blood of lactating goats by using the feed buffer according to the experimental example of the present invention;
FIG. 7C is a graph showing the results of the content detection of inflammatory cytokine TNF- α in blood of lactating goats by the feed buffer according to the experimental examples of the present invention;
FIG. 7D is a diagram showing the results of the content detection of IL-1 β in inflammatory cytokines in blood of lactating goats by using the feed buffer provided in the experimental examples of the present invention.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the accompanying drawings, and it should be understood that the described embodiments are some, but not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It should be noted that:
in the present invention, all embodiments and preferred 10-preferred embodiments mentioned herein can be combined with each other to form a new technical solution, if not specifically stated.
In the present invention, all the technical features mentioned herein and preferred features may be combined with each other to form a new technical solution, if not specifically stated.
In the present invention, the percentage (%) or parts means the weight percentage or parts by weight with respect to the composition, if not otherwise specified.
In the present invention, the components referred to or the preferred components thereof may be combined with each other to form a novel embodiment, if not specifically stated.
In the present invention, unless otherwise stated, the numerical range "a-b" represents a shorthand representation of any combination of real numbers between a and b, where a and b are both real numbers. For example, a numerical range of "3 to 30" means that all real numbers between "3 to 30" have been listed herein, and "3 to 30" is simply a shorthand representation of the combination of these numbers 20.
The "ranges" disclosed herein may have one or more lower limits and one or more upper limits, respectively, in the form of lower limits and upper limits.
In the present invention, unless otherwise specified, the individual reactions or operation steps may be performed sequentially or may be performed in sequence. Preferably, the reaction processes herein are carried out sequentially.
Unless otherwise defined, technical and scientific terms used herein have the same meaning as is familiar to those skilled in the art. In addition, any methods or materials similar or equivalent to those described herein can also be used in the present invention.
The high concentrate can cause the milk yield, milk fat and lactose content of the lactating ruminants to be reduced after long-term feeding, and can also induce the body health of the lactating ruminants to be damaged, and abnormal metabolic products such as SARA, rumen and blood LPS (LPS) and the like to be increased. Based on this, according to one aspect of the present invention, there is provided a feed buffer consisting essentially of:
sodium bicarbonate, magnesium oxide, sodium acetate, and sodium butyrate.
Wherein, the sodium bicarbonate is an acid salt which is alkalescent when dissolved in water, thus playing a role of acid-base buffering for rumen, keeping the pH value (6-7) in a relatively stable state and maintaining an ideal rumen fermentation environment. Food grade calcium bicarbonate is preferably used in the present invention.
The magnesium oxide can maintain beneficial biological flora in gastrointestinal tract, increase the quantity of beneficial bacteria in intestinal tract, and not only has the function of enhancing immunity, but also can supplement the deficiency of magnesium element in daily ration. Food grade magnesium oxide is preferably used in the present invention.
Sodium acetate can increase the concentration of acetic acid in rumen, and acetic acid as precursor of lipid synthesis can be added into ruminant feed to improve the milk fat rate. Food grade sodium acetate is preferred for use in the present invention.
The sodium butyrate can increase the appetite of ruminants, has a certain protection effect on the health of organisms, can change the content of butyric acid in blood, enhances the antioxidant stress capability of mammary glands, reduces apoptosis and further enhances the protection effect on mammary glands. Preferably, food grade sodium butyrate is used in the present invention.
The feed buffer provided by the invention has certain effects of preventing and relieving rumenic acidosis of the ruminant, maintaining the number of beneficial flora in the intestinal tract of the ruminant, improving the health state of an organism, improving the lactation performance of the lactating animal, improving the milk quality, increasing the milk fat, the milk sugar and the milk yield content, and enhancing the protection effect on mammary gland by matching the specific components.
In some preferred embodiments, the feed buffer consists essentially of the following components in parts by weight:
1-10 parts of sodium bicarbonate, 1-10 parts of magnesium oxide, 5-15 parts of sodium acetate and 5-15 parts of sodium butyrate.
The sodium bicarbonate can be, but is not limited to, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts; the magnesium oxide can be, for example, but is not limited to, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, or 10 parts; sodium acetate can be, for example, but is not limited to, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, or 15 parts; the sodium butyrate can be, for example, but not limited to, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, or 15 parts.
The feed buffer agent obtained by limiting the specific mixture ratio of each specific component has better effects of improving ruminant rumen acidosis and improving lactation performance.
In some more preferred embodiments, the feed buffer consists essentially of the following components in parts by weight:
2-8 parts of sodium bicarbonate, 2-8 parts of magnesium oxide, 8-12 parts of sodium acetate and 8-12 parts of sodium butyrate.
In some further preferred embodiments, the feed buffer consists essentially of the following components in parts by weight:
6 parts of sodium bicarbonate, 6 parts of magnesium oxide, 10 parts of sodium acetate and 10 parts of sodium butyrate.
Through further adjustment and optimization of the proportion of the components of the feed buffering agent, the feed buffering agent provided by the invention has better effects of improving ruminant rumen acidosis and improving lactation performance.
According to the second aspect of the invention, the preparation method of the feed buffer is also provided, wherein the feed buffer is obtained by uniformly mixing the sodium bicarbonate, the magnesium oxide, the sodium acetate and the sodium butyrate according to the weight parts of the formula.
The preparation method of the feed buffer provided by the invention has the advantages of simple process and convenience in operation, a large amount of manpower and material resources can be saved, the cost is reduced, and the prepared feed buffer has good effects of improving ruminant rumen acidosis and improving lactation performance.
According to the third aspect of the invention, the application of the feed buffer or the feed buffer prepared by the preparation method in the preparation of products for preventing and/or treating ruminant rumen acidosis is also provided.
The feed buffer provided by the invention can play a role in acid-base buffering on rumen and maintain an ideal rumen fermentation environment, so that the feed buffer provided by the invention can be used for preparing products for preventing and/or treating ruminant rumen acidosis.
The product can be, but is not limited to, feed, medicine, health product, etc.
It is understood that "prevention and/or treatment" means that the product has a prophylactic effect, or has a therapeutic effect, or has both a prophylactic and a qualitative effect.
In prophylactic applications, relatively low doses may be administered chronically at relatively infrequent intervals. In therapeutic applications, it is sometimes desirable to administer relatively high doses at relatively short intervals until the progression of the disease is delayed or halted, preferably until the individual exhibits a partial or complete improvement in the symptoms of the disease, after which a prophylactic regimen may be administered.
In some preferred embodiments, the product is a feed.
According to a fourth aspect of the present invention, there is also provided a feed comprising a basal feed and the feed buffer described above or prepared by the preparation method described above.
The feed can effectively improve the lactation performance of the lactating animals on the basis of ensuring the nutrition supply, and simultaneously prevent and/or treat ruminant rumen acidosis. The feed is supplemented with a proper amount of feed buffer, which is a beneficial feeding mode.
In some preferred embodiments, the basal feed comprises a roughage and/or a concentrate.
The coarse fodder is fodder with natural water content below 60% and crude fiber content equal to or higher than 18% and fed in air-dried form, such as pasture, crop straw, distiller's grains, etc. Concentrated feed, also called concentrate, is a feed containing rich nutrients, low crude fiber content and high digestible nutrients in unit volume or unit weight, relative to coarse feed, and mainly comprises seeds of crops (grains, beans and seeds of oil crops) and by-products of processing.
Preferably, the basal feed comprises a concentrate.
When the requirement of high energy of the dairy cows or dairy goats in the lactation period is met by adding the concentrated feed, the pH value of the rumen is reduced, and the risk of subacute rumen acidosis is higher, so that the feed buffer is added into the concentrated feed to achieve better prevention and treatment effects.
In some preferred embodiments, the mass ratio of the basic feed to the feed buffer is 25-35: 1, such as, but not limited to, 25: 1, 26: 1, 27: 1, 28: 1, 29: 1, 30: 1, 31: 1, 32: 1, 33: 1, 34: 1 or 35: 1, and when the mass ratio of the basic feed to the feed buffer is within the above range, the mixed feed can have good effects of improving ruminant rumen acidosis and improving lactation performance on the basis of ensuring nutrition supply.
Preferably, the mass ratio of the basal feed to the feed buffer is 31: 1.
By further adjusting and optimizing the mass ratio of the basic feed to the feed buffering agent, the feed obtained by mixing has better effects of improving ruminant rumen acidosis and improving lactation performance on the basis of ensuring nutrition supply.
The present invention will be further described with reference to specific examples and comparative examples.
Example 1
The embodiment provides a feed buffer which mainly comprises the following components in parts by weight:
1 part of sodium bicarbonate, 10 parts of magnesium oxide, 5 parts of sodium acetate and 15 parts of sodium butyrate.
Example 2
The embodiment provides a feed buffer which mainly comprises the following components in parts by weight:
10 parts of sodium bicarbonate, 1 part of magnesium oxide, 15 parts of sodium acetate and 5 parts of sodium butyrate.
Example 3
The embodiment provides a feed buffer which mainly comprises the following components in parts by weight:
2 parts of sodium bicarbonate, 8 parts of magnesium oxide, 8 parts of sodium acetate and 12 parts of sodium butyrate.
Example 4
The embodiment provides a feed buffer which mainly comprises the following components in parts by weight:
8 parts of sodium bicarbonate, 2 parts of magnesium oxide, 12 parts of sodium acetate and 8 parts of sodium butyrate.
Example 5
The embodiment provides a feed buffer which mainly comprises the following components in parts by weight:
6 parts of sodium bicarbonate, 6 parts of magnesium oxide, 10 parts of sodium acetate and 10 parts of sodium butyrate.
Example 6
The embodiment provides a feed buffer which mainly comprises the following components in parts by weight:
12 parts of sodium bicarbonate, 15 parts of magnesium oxide, 3 parts of sodium acetate and 18 parts of sodium butyrate.
Comparative example 1
The comparative example provides a feed buffer, which mainly comprises the following components in parts by weight:
6 parts of magnesium oxide, 10 parts of sodium acetate and 10 parts of sodium butyrate.
Comparative example 2
The comparative example provides a feed buffer, which mainly comprises the following components in parts by weight:
6 parts of sodium bicarbonate, 10 parts of sodium acetate and 10 parts of sodium butyrate.
Comparative example 3
The embodiment provides a feed buffer which mainly comprises the following components in parts by weight:
6 parts of sodium bicarbonate, 6 parts of magnesium oxide and 10 parts of sodium butyrate.
Comparative example 4
The embodiment provides a feed buffer which mainly comprises the following components in parts by weight:
6 parts of sodium bicarbonate, 6 parts of magnesium oxide and 10 parts of sodium acetate.
Examples of the experiments
The 12 Saaner dairy goats (39 +/-7 kg, Mean +/-SEM kg and 2-3 weeks after delivery) with similar body weight and lactation period used in the experimental example have good health conditions, are purchased from test farms of northwest agriculture and forestry science and technology university and are bred in animal physical and chemical key laboratory of agriculture department of Nanjing agriculture university.
After all animals are adapted to one week by high-precision feeding, rumen fistula and liver blood fistula are respectively arranged on the test animals, and the test animals recover for 2 weeks after the operation. In order to keep hepatic vascular fistula open, 0.3mL (500IU/mL) of heparin sodium normal saline solution is injected into each fistula every 8h until the test is finished.
After the recovery period, the lactating goats were randomly divided into 11 groups of 6 High concentrate group (HG) and feed buffer groups 1-10 (BG, 1-10 correspond to inventive examples 1-6 and comparative examples 1-4). The animals in the two groups were fed the same basic ration, the mass ratio of the fed fine and coarse ration was 60: 40, and the formula is shown in table 1. Buffer
The formulation was supplemented with the feed buffers provided in examples 1-6 of the present invention and comparative examples 1-4 on a basal ration basis. The test period is 20 weeks, and the animals are raised in a single cage, during which water is freely drunk.
TABLE 1 test diet and nutritional composition
Note: a. every kilogram of daily ration provides VD 2500 IU, VA 6000 IU, VE 80mg, copper 6.25mg, iron 62.5mg, zinc 62.5mg, manganese 50mg, iodine 0.125mg and cobalt 0.125 mg; b. nutrition levels were calculated according to the NRC (2001) method. Note: rendered per kg of die: vitamin A6,000 IU, vitamin D2,500 IU, vitamin E80 mg, Cu 6.25mg, Fe 62.5mg, Zn 62.5mg, Mn 50mg, I0.125 mg, Co 0.125mg. b Nutrient levels measured and recorded to National Research Council methods (2001).
The duration of the experiment was 2 milkings per day (time: 8: 00 am and 18: 00 am). Milk was discarded before 3, weighed after milking and milk production recorded. Rumen fluid was collected through the rumen fistula once every two weeks for pH determination. The results are shown in table 2 below.
TABLE 2 milk yield and rumen pH measurements
Group of | Milk yield | Rumen pH |
High concentrate group | 1.15±0.12 | 5.70±0.12 |
|
1.22±0.10 | 6.18±0.13 |
|
1.21±0.11 | 6.16±0.16 |
|
1.25±0.13 | 6.26±0.13 |
|
1.24±0.21 | 6.25±0.11 |
|
1.28±0.15 | 6.40±0.14 |
|
1.20±0.17 | 6.13±0.10 |
|
1.18±0.16 | 6.14±0.12 |
|
1.17±0.15 | 6.11±0.17 |
|
1.19±0.13 | 6.13±0.13 |
|
1.16±0.10 | 6.12±0.11 |
From the above results, it can be seen that the feed buffers provided in examples 1 to 6 of the present invention have good effects of improving rumen acidosis and improving lactation performance in ruminants due to the synergistic combination of the specific components. The feed buffers provided in comparative examples 1 to 4 were not as effective as those of the examples of the present invention in terms of milk production and rumen pH improvement.
The feed buffers provided in examples 1-6 are completely the same in raw material components and only different in proportioning, but the feed buffers provided in examples 1-5 are superior to those in example 6 in both milk yield and rumen pH improvement, which indicates that the feed buffers provided in the present invention have better effects of improving ruminant rumen acidosis and improving lactation performance under the preferable proportioning conditions of the present invention.
Moreover, the effect of example 5 is better than that of examples 1-4, and the effect of examples 3 and 4 is better than that of examples 1 and 2, which shows that the feed buffer provided by the invention has better effects of improving ruminant rumen acidosis and improving lactation performance by further adjusting and optimizing the component ratio.
The feed buffer provided in example 5 and comparative examples 1 to 4 have the same mixture ratio of the same components, but the feed buffer provided in example 5 has better levels than those of comparative examples 1 to 4 in terms of milk yield and rumen pH improvement due to the absence of sodium bicarbonate in comparative example 1, magnesium oxide in comparative example 2, sodium acetate in comparative example 3 and sodium butyrate in comparative example 4, which shows that the feed buffer provided in the invention has better effects of improving ruminant rumen acidosis and improving lactation performance only through synergistic cooperation between specific components of each raw material under the condition that the mixture ratio of the components of the same raw materials is the same.
In order to save costs, example 5, which is superior in the above effects, was selected as the feed buffer group and the high-concentrate group for the test.
Milk sample collection and milk component content determination
The duration of the experiment was 2 milkings per day (time: 8: 00 am and 18: 00 am). Milk was discarded before 3, weighed after milking and milk production recorded.
The milk fat and lactose contents were measured once a week. Sending to milk industry detection center of Nanjing Weigang of Jiangsu province, and detecting milk fat, lactose, etc. content with milk component analyzer.
1. Influence of feed buffer on milk yield of lactating goat fed with high-precision feed
As shown in FIG. 1, the milk production of the two groups of goats at the first 2 weeks of the experiment was substantially similar, and the milk production of the lactating goats in the buffer group was higher than that in the high-formula group from week 3, wherein the milk production was significantly higher than that in the high-formula group from week 8 (1.26. + -. 0.14vs 1.15. + -. 0.12, P < 0.05), and continued until week 15 to 16-19, and the milk production of the lactating goats in the buffer group was also higher than that in the high-formula group, but the difference was not significant (P > 0.05).
2. Effect of feed buffer on the milk fat content of lactating goats
As can be seen from FIG. 2, the difference in the milk fat rates of the two groups of goats from week 1 to week 5 was small, and the trends were that the milk fat rates were increased first, then decreased, and then increased. Beginning at week 6, the milk fat content of the buffer group began to be higher than that of the high-profile group, wherein the milk fat rate of the buffer group reached a maximum of 3.60 ± 0.13% at week 10, and the milk fat rate of the buffer group began to decrease at week 18.
3. Effect of Complex buffer on lactose content in lactating goats
As can be seen from fig. 3, the lactose content was substantially consistent for the first 3 weeks of the experiment. The lactose content in the buffer group was higher than that in the high-concentrate group starting at week 4, the lactose content reached the highest at week 6 and was significantly higher than that in the high-concentrate group (3.42. + -. 0.12 vs. 2.80. + -. 0.11, P < 0.05), and the buffer group was higher than that in the high-concentrate group by week 7 to the end of the experiment.
Second, blood sample collection
Jugular vein blood was collected from the last 1d of the trial to week 19. The collected blood sample is quickly transferred into an anticoagulant tube containing heparin sodium, centrifuged for 12min at 4 ℃ and 2500 Xg, and serum is separated into an EP tube and stored at-20 ℃ to be tested.
1. Blood biochemical index determination
Taking 1mL of the collected jugular vein blood sample, sending to a department of hematology of the Chinese and Western medicine combination hospital in Nanjing, and detecting biochemical indexes of blood by using a full-automatic biochemical analyzer, wherein the biochemical indexes include indexes such as Alanine transaminase (ALT), Glutamic-oxaloacetic transaminase (AST), Total Bilirubin (TB), Alkaline phosphatase (AKP), Triglyceride (Triglyceride, TG), Lactate Dehydrogenase (LDH), Hypersensitive C-reactive protein (HS-CRP) and the like.
As shown in Table 3, the buffer group has lower ALT, AST and AKP content than the high concentrate group in the blood of the lactating goats, and the difference is significant (P is less than 0.05), which indicates that the liver injury state of the lactating goats is relieved. The content of TB in the blood of the buffer group is obviously higher than that of the high-precision group (P is less than 0.05), and no obvious difference exists between the two groups of other indexes.
TABLE 3 Effect of Complex buffers on biochemical indices related to lactation goat blood (n ═ 6)
2. Blood hormone index detection
Collecting jugular vein blood sample, and determining related hormone content by adopting ELISA detection kit of Insulin (INS), glucagon, cortisol and insulin-like growth factor-1, wherein the test steps are carried out according to the kit instruction. The results are shown in Table 4. Generally, the endocrine hormones in the animal body are at a normal physiological level under normal conditions. Mainly secreted by some specific organs and entered into the circulating blood in a dispersed manner to play a role in the target tissue. As can be seen from table 4, the complex buffer resulted in an increase in the amount of INS in the blood. INS can regulate glycolipid metabolism in the body. The increase of INS content in blood suggests that it may play a role in the major organs (liver) of body's glycolipid metabolism.
Table 4 effect of complex buffer on the blood hormone content of lactating goats (n ═ 6)
Note: indicates significant difference (P < 0.05) compared to the high concentrate group.
Note:Compared with the high concentrate group,*indicates a significant difference(P<0.05).
3. Measurement of blood metabolic abnormality product and inflammatory factor
Measuring histamine in jugular vein blood by adopting an ELISA method, measuring the absorbance content of each hole at the wavelength of 450nm, and calculating the concentration of a sample by a regression equation, wherein the unit is expressed by ng/mL; the lactic acid content is determined by a lactic acid dehydrogenase method, the absorbance content of each hole is determined at the wavelength of 530nm, and the concentration of the sample is calculated by a regression equation, wherein the unit is expressed by mmol/L. The operation steps are respectively carried out according to the relevant specifications. The results are shown in FIGS. 7A and 7B.
Inflammatory cytokines TNF-alpha and IL-1 beta in jugular vein blood are detected by a 125I radioimmunoassay kit. The operation steps are carried out according to the instruction. As shown in fig. 7C and 7D, the study found that high-quality diet can induce SARA in the body of lactating goats, the increased LPS in rumen fluid enters the blood through the rumen wall, and the contents of lactic acid and TNF-alpha in the blood are significantly increased, which causes inflammation in the body. After the compound buffer is added, no SARA state appears, and simultaneously, the contents of LPS released by rumen, metabolic abnormal products and inflammatory factors in blood are obviously reduced. The composite buffering agent can relieve the decrease of rumen pH value caused by high-precision feeding, reduce the release of LPS and the like, and improve the health state of organisms.
Thirdly, collecting rumen fluid and measuring pH
1. Determination of the pH of rumen fluid
Rumen fluid was collected through the rumen fistula once every two weeks for pH determination. The specific method comprises the following steps: rumen contents are collected from 15min before ingestion and 0, 2, 4, 6, 8 and 10h after feeding, and rumen fluid is filtered and collected by sterilized medical gauze. The pH was determined immediately and three consecutive measurements were made per test animal.
By detecting the average pH values of rumen fluid at 0, 2, 4, 6, 8 and 10h after 2-18 weeks of feeding, the result is shown in figure 4, and the total change trend of rumen pH value is firstly decreased and then increased. After the feeding, the pH value is in a descending trend, after 4 hours, the pH value is reduced to the minimum value (5.65 +/-0.03), and then the pH value is gradually increased to the initial level due to the strong buffering capacity of the rumen. However, the pH value of the rumen fluid of the lactating goats in the buffering agent group is higher than that in the high-precision material group (6.0 +/-0.10 vs 5.8 +/-0.08).
When SARA is taken as the time that the pH value of the rumen is less than 5.8 per day and is not less than 4h, SARA phenomenon begins to appear after the high-feed group of lactating goats eat the feed for 2 h. And after the compound buffering agent is added, the decrease of the pH value of the rumen caused by high-precision materials is relieved, so that the pH value of rumen fluid is stabilized.
2. Determination of rumen content and LPS content in blood
Diluting rumen fluid and blood sample by 5 times with sample diluent in the kit, loading according to LPS enzyme-linked immunoassay kit instruction, sequentially determining absorbance value (OD) of each well at 450nm wavelength, and calculating LPS content (activity unit is EU/mL) in rumen fluid and blood by using standard curve equation with blank well zeroing as reference. LPS standard curve equation: 1445.5x-92.211, R20.9995(y represents concentration and x represents OD value).
By detecting the contents of LPS in gastric juice and blood of two groups of lactating goats, the results of the two groups of rumens and blood show that the content of LPS (26201.41 +/-2398.18 vs 40395.43 +/-4723.14, P < 0.01) in rumens of the buffer group is remarkably lower than that of the high-concentrate group, and the content of LPS (2.01 +/-0.24 vs 3.62 +/-0.50, P < 0.05) in blood is remarkably lower than that of the high-concentrate group in the buffer group. The pH level of the rumen of the lactating goat is stabilized by adding the compound buffering agent, so that the generation of an abnormal product LPS in the rumen is reduced.
3. Determination of Volatile Fatty Acid (VFA) content in rumen fluid and blood
And (3) rumen fluid treatment: adding 1mL rumen fluid into EP tube, adding 25% metaphosphoric acid mixed solution (containing 0.2mL crotonic acid), mixing well, storing at-20 deg.C overnight, standing at room temperature for thawing, centrifuging at 4 deg.C and 12000 Xg for 10min, and filtering supernatant with needle filter (0.22 μm).
Blood treatment: adding 200 μ L of plasma into EP tube, adding 200 μ L of 5% sulfosalicylic acid mixture (precipitated protein) containing crotonic acid, mixing, storing at-20 deg.C overnight, centrifuging at 4 deg.C and 12000 Xg for 30min, collecting supernatant, filtering with needle filter, and testing. As shown in tables 5 and 6, the present study found that the addition of complex buffer not only improved the decrease in rumen pH due to the excessive concentrate ratio, but also changed the content and ratio of VFA in rumen and blood. The main reasons for this are the buffering effect of sodium bicarbonate on the one hand, and the weak acids of acetic acid and butyric acid on the other hand, which combine with hydrogen ions in the rumen to form weak acids after entering the rumen, so as to inhibit the decrease of the pH value. And the content of butyric acid in blood is also obviously increased by the absorption of rumen epithelium. The increase in blood butyrate concentration in this test. Probably due to the addition of sodium butyrate to the feed. Butyric acid, as a main component of sodium butyrate, is increasingly important in the aspects of gastrointestinal health and anti-inflammation at present, and can relieve damage of liver cells caused by high-concentrate feeding. Therefore, elevated butyrate in blood may play a role in protecting the health of the body.
Table 5 effect of complex buffer on rumen VFA of lactating goats (n ═ 6)
Note: indicates significant difference (P < 0.05) compared to the high concentrate group.
Note:Compared with the high concentrate group,*indicates a significant difference(P<0.05).
Table 6 effect of complex buffer on blood VFA of lactating goats (n ═ 6)
Note: indicates significant difference (P < 0.05) compared to the high concentrate group.
Note:Compared with the high concentrate group,*indicates a significant difference(P<0.05).
Fourthly, determination of mammary gland oxidative stress index and tissue apoptosis related protein
1. The antioxidant stress index measured in the test comprises glutathione peroxidase (GSH-PX), Superoxide dismutase (SOD), Catalase (CAT), Total antioxidant capacity (T-AOC) and Malondialdehyde (MDA). The measurement of various indexes is carried out by adopting an enzyme-linked immunosorbent assay. The kits were purchased from Nanjing, institute for bioengineering.
As shown in Table 7, the antioxidant stress indexes SOD, CAT and T-AOC of the mammary gland of the lactating goat in the buffer group are all higher than those in the high-precision group, wherein the CAT and the T-AOC are significantly higher than those in the high-precision group (P is less than 0.05). While the oxidative stress index MDA is obviously lower than that of the high concentrate group (P is less than 0.05); the buffer group GSH-PX was lower than the high concentrate group, but there was no significant difference (P > 0.05). The fact that the compound buffering agent is added improves the breast oxidative stress state of the lactating goats induced by high-precision feeding.
TABLE 7 Effect of Complex buffers on oxidative stress indicators of lactating goat mammary glands (n ═ 6)
Note: indicates significant difference (P < 0.05) compared to the high concentrate group.
2. Western Blot detection of mammary tissue apoptosis-related protein
Wherein the Caspase-3, Caspase-9 and Bcl-2 primary antibodies are diluted by 1: 1000 times; diluting the Bax primary antibody by 1: 2000 times; the internal control GAPDH is diluted by 1: 5000 times.
(1) Protein sample extraction
Preparing precooled RIPA lysate (containing PMSF with concentration of 1 mmol/L), taking about 80mg of liver, and homogenizing on ice for about 5 min; standing for 30min, centrifuging at 4 deg.C and 12000 Xg for 20min in a high speed centrifuge, and collecting supernatant. The protein concentration was determined by total protein quantitation, with the steps performed strictly according to the instructions. Adjusting the protein concentration to the same concentration, and subpackaging in EP tubes at-80 deg.C for use.
(2) SDS-PAGE electrophoresis and Wet transfer
Separating gel (10%) and concentrating gel (5%) were prepared. And (3) sampling 60 mu g of denatured protein, carrying out 80V constant-pressure ice bath electrophoresis for 30min by using a protein standard substance marker with the sampling amount of 4 mu L, and then changing to 110V constant pressure until the ice bath electrophoresis is finished.
Intercepting the gel at the corresponding position of the target protein, and cutting the PVDF membrane according to the size of the gel. Activating the cut PVDF membrane by methanol for 10-20s, and then putting the gel, the filter paper and the PVDF membrane into the transfer printing liquid for soaking for 10 min. From the positive electrode to the negative electrode are: filter paper, PVDF membrane, gel, filter paper, wet transfer printed for 1.5h with 100V constant pressure.
(3) Blocking and antibody incubation
And (3) sealing: the transferred PVDF membrane was removed, and the protein was blocked with skimmed milk powder (5%) blocking solution on a shaker at room temperature for 2 h.
Antibody incubation: after the blocking is finished, the blocking solution is discarded. Rabbit anti-primary antibody was diluted 1: 1000 times, GAPDH was diluted 1: 5000 times, and incubated overnight at 4 ℃. After incubation of primary antibody was complete, primary antibody was gently aspirated and membrane washed 5 times with TBST for 10min each. Then, a secondary goat anti-rabbit antibody, which was diluted with TBST at 1: 10000 times, was added and incubated at room temperature for 2 h. After the secondary antibody incubation is finished, the membrane washing process is repeated.
(4) Color development and analysis
After the membrane is sucked dry by filter paper, ECL luminous liquid is quickly added, after the membrane is kept out of the sun for 5min, the membrane is developed by a full-automatic chemiluminescence image analysis system, and the gray value of each group of strips is observed. The band intensity values were analyzed by Image J software to calculate the relative expression levels of the respective target proteins.
Results are shown in fig. 6A, 6B, 6C and 6D, Caspase-3(0.65 ± 0.05 vs. 1.00 ± 0.25) and Bax (0.74 ± 0.08 vs. 1.00 ± 0.22) protein expression was significantly down-regulated (P < 0.05) in mammary glands of lactating goats after the addition of complex buffer; and the expression level of the anti-apoptotic protein Bcl-2(1.52 +/-0.18 vs 1.00 +/-0.11) is obviously up-regulated (P < 0.05). The result of the oxidative stress index is combined to prompt that the high-precision feed feeding induces the oxidative stress of the mammary gland of the lactating goat to cause the apoptosis injury of the mammary gland. The addition of the compound buffer can improve the stress or apoptosis injury of mammary glands induced by high-precision feeding of the lactating goats.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
1. A feed buffer, characterized in that said feed buffer consists essentially of:
sodium bicarbonate, magnesium oxide, sodium acetate, and sodium butyrate.
2. The feed buffer of claim 1, wherein the feed buffer consists essentially of the following components in parts by weight:
1-10 parts of sodium bicarbonate, 1-10 parts of magnesium oxide, 5-15 parts of sodium acetate and 5-15 parts of sodium butyrate.
3. The feed buffer of claim 2, wherein the feed buffer consists essentially of the following components in parts by weight:
2-8 parts of sodium bicarbonate, 2-8 parts of magnesium oxide, 8-12 parts of sodium acetate and 8-12 parts of sodium butyrate.
4. The feed buffer of claim 3, wherein the feed buffer consists essentially of the following components in parts by weight:
6 parts of sodium bicarbonate, 6 parts of magnesium oxide, 10 parts of sodium acetate and 10 parts of sodium butyrate.
5. The method for preparing a feed buffer according to any one of claims 1 to 4, wherein the feed buffer is obtained by uniformly mixing sodium bicarbonate, magnesium oxide, sodium acetate and sodium butyrate in parts by weight of a formulation.
6. Use of a feed buffer according to any of claims 1-4 or prepared by the preparation method of claim 5 for the preparation of a product for the prevention and/or treatment of ruminal acidosis in a ruminant.
7. Use according to claim 6, wherein the product comprises a feed.
8. A feed comprising a basal feed and a feed buffer according to any one of claims 1 to 4 or prepared by the preparation method according to claim 5.
9. The feed of claim 8, wherein the basal feed comprises a roughage and/or a concentrate;
preferably, the basal feed comprises a concentrate.
10. The feed according to claim 8 or 9, wherein the mass ratio of the basal feed to the feed buffer is 25-35: 1, preferably 31: 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010359860.XA CN113558146A (en) | 2020-04-29 | 2020-04-29 | Feed buffering agent, preparation method and application thereof, and feed using feed buffering agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010359860.XA CN113558146A (en) | 2020-04-29 | 2020-04-29 | Feed buffering agent, preparation method and application thereof, and feed using feed buffering agent |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113558146A true CN113558146A (en) | 2021-10-29 |
Family
ID=78158673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010359860.XA Pending CN113558146A (en) | 2020-04-29 | 2020-04-29 | Feed buffering agent, preparation method and application thereof, and feed using feed buffering agent |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113558146A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116850168A (en) * | 2023-07-19 | 2023-10-10 | 邢台学院 | Method for treating mastitis by sodium butyrate |
BE1030991B1 (en) * | 2022-10-26 | 2024-05-27 | Vds Nv | PENAL BUFFER COMPOSITION |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102068454A (en) * | 2011-01-13 | 2011-05-25 | 王之盛 | Slow-release regulating agent for preventing rumen acidosis and preparation method thereof |
-
2020
- 2020-04-29 CN CN202010359860.XA patent/CN113558146A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102068454A (en) * | 2011-01-13 | 2011-05-25 | 王之盛 | Slow-release regulating agent for preventing rumen acidosis and preparation method thereof |
Non-Patent Citations (5)
Title |
---|
孙瑞涛等: "奶牛亚临床酸中毒的危害及防治", 饲料工业 * |
征黎: "高精料日粮对反刍动物肝脏NOD样受体表达的影响和调控", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
李振富: "高精料日粮条件下反刍动物瘤胃中产生的组胺对肝脏炎性信号通路的影响与调控", 《中国优秀硕士学位论文全文数据库农业科技辑》 * |
李林等: "添加复合缓冲剂对高精料饲喂泌乳奶山羊乳品质的改善及机制", 食品科学 * |
郭峻菲: "亚急性瘤胃酸中毒(SARA)对反刍动物肝脏的炎性损伤与SARA的调控研究", 《中国博士学位论文全文数据库 农业科技辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1030991B1 (en) * | 2022-10-26 | 2024-05-27 | Vds Nv | PENAL BUFFER COMPOSITION |
CN116850168A (en) * | 2023-07-19 | 2023-10-10 | 邢台学院 | Method for treating mastitis by sodium butyrate |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cohen-Zinder et al. | Effect of feeding lactating cows with ensiled mixture of Moringa oleifera, wheat hay and molasses, on digestibility and efficiency of milk production | |
Piccioli-Cappelli et al. | Effect of dietary starch level and high rumen-undegradable protein on endocrine-metabolic status, milk yield, and milk composition in dairy cows during early and late lactation | |
Shabtay et al. | Effects of adding a concentrated pomegranate extract to the ration of lactating cows on performance and udder health parameters | |
Mohri et al. | Effects of parenteral supply of iron on RBC parameters, performance, and health in neonatal dairy calves | |
Johansson et al. | Status of vitamins E and A and β-carotene and health in organic dairy cows fed a diet without synthetic vitamins | |
Facciolongo et al. | Alternative protein sources in lamb feeding 1. Effects on productive performances, carcass characteristics and energy and protein metabolism | |
CN113558146A (en) | Feed buffering agent, preparation method and application thereof, and feed using feed buffering agent | |
Ata et al. | The inclusion of sweet lupin grain (Lupinus angustifolius) improves nursing performance of lactation in Awassi ewes | |
El-Ghousein | Effect of some medicinal plants as feed additives on lactating awassi ewe performance, milk composition, lamb growth and relevant blood items | |
Ghoniem et al. | Effect of addition protected fatty acids in ruminant rations on productive performance of suffolk x ossimi crossbred ewes during different production stages | |
Allam et al. | Effect of feeding dried orange pulp to lactating dairy cows on nutrients digestibility, blood constituents, plasma antioxidant biomarker, and pathogenic fecal bacteria | |
Al-Abbasy | Effect of adding two levels of niacin in milk production and controlling indicators of ketosis in Friesian cows postpartum | |
Salgado-Hernández et al. | Effect of the first and second postpartum partial milking on blood serum calcium concentration in dairy cows. | |
Ibrahim et al. | Experimental study on zinc deficiency in sheep | |
US20130040902A1 (en) | Method for enhancing milk quantity and quality | |
Mahmoud et al. | Influence of feeding garlic plant either as powder or oil on reproductive performance of ewes | |
RU2649593C1 (en) | Immunomodulating selenium-organic coniferous complex preparation | |
Aoki et al. | Effect of Saccharomyces cerevisiae fermentation product on ruminal fermentation, blood metabolites, and milk production in dairy cows | |
Ramella et al. | Effects of postpartum treatment with oral calcium formate on serum calcium, serum metabolites, and the occurrence of diseases at the beginning of lactation of high-producing dairy cows | |
Kenna et al. | Evaluation of N-Hydroxymethyl-DL-Methionine-Ca and Di-Hydroxymethyl-L-Lysine-Ca in a blended corn based ration for lactating cows | |
Abu El-Ella et al. | Reproductive performance and blood constituents of Damascus goats as affected by yeast culture supplementation | |
Abu El-Ella et al. | Studying the effect of antioxidants (Origanum Vulgare and N-Acetylcysteine) administration on productive and reproductive performance of Damascus goats and their offspring. | |
Mikuła et al. | Effect of different pre-calving feeding strategies on the metabolic status and lactation performance of dairy cows | |
CN115769856B (en) | Milk secretion cow feed added with red date powder for improving milk flavor and preparation method thereof | |
YADAV | EFFECT OF MICRONUTRIENT ADMINISTRATION ON THE HEALTH AND PRODUCTIVITY OF TRANSITION CROSSBRED COWS AND THEIR CALVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211029 |